Results

Search Results

Page

No results.

Team

  • Holger Reithinger

    forbion.com/en/team/holger_reithinger
    Holger joined FORBION Capital Partners in 2010, heading the Munich office. He holds a PhD in Biochemistry, which he obtained under the supervision of Prof. Dr. Arne Skerra (founder of FORBION's port...
  • Philip Astley-Sparke

    forbion.com/en/team/philip_astley_sparke
    Philip Astley-Sparke is the former President and CEO of BioVex Group Inc. / Limited. He also acted as the company’s Chairman from November 2009 until March 2011, when the company was acquired ...
  • Sander Slootweg

    forbion.com/en/team/sander_slootweg
    Sander is Managing Partner and co-founded ABN AMRO Capital Life Sciences in 2000 and Forbion Capital Partners in 2006. At Forbion, Sander is responsible for Fundraising, Investor- and Public Relatio...
  • Martien van Osch

    forbion.com/en/team/martien_van_osch
    Martien is a founding partner at Forbion Capital Partners. He splits his time between investment related activities and the finance function. In terms of investment focus, Martien spearheads the med...
  • Marco Boorsma

    forbion.com/en/team/marco_boorsma
    Marco is General Partner at Forbion Capital Partners and joined the team in 2007. Marco has a background in molecular biology and biotechnology and brings operational and business development experi...
  • Sander van Deventer

    forbion.com/en/team/sander_van_deventer
    Sander van Deventer has had a critical role in the development of the first commercial monoclonal antibody (Remicade) and the first gene therapy to be granted market authorization in the Western world...
  • Rogier Rooswinkel

    forbion.com/en/team/rogier_rooswinkel
    Rogier is Principal at the Naarden office and joined Forbion in 2013. Rogier has a background in Medical Sciences, and in 2008 finished a Master of Oncology at the Free University in Amsterdam. In t...
  • Geert-Jan Mulder

    forbion.com/en/team/geert_jan_mulder
    Geert-Jan Mulder MD, co-founding partner of Forbion, is an experienced life sciences investor who led multiple deals in both Europe and the US. Geert-Jan led the firm’s successful investments ...
  • Mathias Falcenberg

    forbion.com/en/team/mathias_falcenberg
    Mathias joined Forbion as Analyst in 2016 and is located in the Munich Office. Before, he was project leader for metabolic therapy at the Max Planck Institute of Biochemistry (MPIB) responsible for ...
  • Cyril Lesser

    forbion.com/en/team/cyril_lesser
    Cyril joined Forbion Capital Partners in October 2009 as Controller. His main focus lies in the financial and treasury operations as well as the accounting and tax reporting for all Forbion Capital ...

News

Portfolio

  • Akarna Therapeutics

    forbion.com/en/portfolio/akarna_therapeutics
    Akarna Therapeutics is a biopharmaceutical company developing novel small molecule therapeutics that target inflammatory and fibrotic diseases. Akarna’s lead program is a potential best-in-class...
  • Allecra Therapeutics

    forbion.com/en/portfolio/allecra_therapeutics
    Allecra Therapeutics is a biopharmaceutical company established in 2013 focussed on the development of novel treatments to combat multi drug-resistant bacterial infections.
  • AM-Pharma

    forbion.com/en/portfolio/am_pharma
    AM-Pharma is a biopharmaceutical company developing a novel recombinant human alkaline phosphatase for treatments of severe inflammatory mediated diseases. Alkaline Phosphatase plays a key role as an ...
  • Amakem

    forbion.com/en/portfolio/amakem
    Amakem is a kinase platform company focusing on ophthalmology, respiratory and gastroenterology. Amakem's product pipeline is based on its ‘Localized Drug Action' platform that generates novel k...
  • arGEN-X

    forbion.com/en/portfolio/argen_x
    ArGEN-X focuses on the discovery and development of human antibodies using its proprietary SIMPLE Antibody (TM) platform. The platform generates a limitless source of extremely high quality human anti...
  • Argos Therapeutics

    forbion.com/en/portfolio/argos_therapeutics
    Argos is focused on the treatment of metastatic cancers and chronic infections using a proprietary platform technology that stimulates immune cells with messenger RNA. The company’s lead produc...
  • Ario Pharma

    forbion.com/en/portfolio/ario_pharma
    Ario Pharma is a clinical-stage company developing a novel therapeutic approach to overactive bladder, an area of significant unmet medical need. The Company’s development compound, XEN-D0501, t...
  • Autonomic Technologies Europe

    forbion.com/en/portfolio/autonomic_technologies_europe
    Autonomic Technologies Europe GmbH is a 100% subsidiary of Autonomic Technologies, Inc. (ATI), a medical device company located in the San Francisco Bay Area focused on the development and commerciali...
  • Cellnovo

    forbion.com/en/portfolio/cellnovo
    Based in France and the United Kingdom, Cellnovo has developed and markets a second generation insulin patch pump that helps make life easier for diabetics type 1. Compact, tubeless, intuitive and ent...
  • Curetis

    forbion.com/en/portfolio/curetis
    Curetis AG is a molecular diagnostic company focusing on the development and commercialization of a universal molecular diagnostics solution for easy-to-use, fast and reliable molecular disease testin...